From the Research
Lanreotide, a somatostatin analogue, can potentially affect libido in some patients, although the evidence is limited and indirect, and the most recent high-quality studies do not specifically address this issue 1, 2. The medication works by inhibiting various hormones, including growth hormone and insulin-like growth factor-1, which may indirectly impact sexual function. The mechanism likely involves lanreotide's effects on the hypothalamic-pituitary axis, which regulates sex hormone production. Some studies suggest that hormonal changes, such as those induced by lanreotide, can affect libido, but these findings are not specific to lanreotide and are based on its mechanism of action and the effects of similar medications 3. Patients experiencing changes in sexual desire while on lanreotide should discuss these symptoms with their healthcare provider, as dosage adjustments or alternative management strategies might be considered. However, it's essential to note that the underlying conditions being treated with lanreotide, such as acromegaly or neuroendocrine tumors, may themselves affect libido, making it challenging to determine whether symptoms are medication-related or disease-related 4, 5. Key points to consider include:
- Lanreotide's potential impact on libido is indirect and related to its hormonal effects
- The medication's primary use is for conditions like acromegaly and neuroendocrine tumors, which may have their own effects on sexual function
- Patients should discuss any changes in libido with their healthcare provider to determine the best course of action
- The evidence base for lanreotide's effects on libido is limited, and more research is needed to fully understand this potential side effect.